Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.

Oncotarget - 18 Apr 2017

Bjoern Jon, Lyngaa Rikke, Andersen Rikke, Hölmich Lisbet Rosenkrantz, Hadrup Sine Reker, Donia Marco, Svane Inge Marie

Abstract excerpt

INTRODUCTION: Tumour infiltrating lymphocyte (TIL) based adoptive cell therapy (ACT) is a promising treatment for patients with advanced melanoma. Retrospective studies suggested an association between previous treatment with anti-CTLA-4 antibodies and long term survival after subsequent ACT. Thus, we hypothesized that treatment with anti-CTLA-4 antibodies can induce favourable changes to be detected in TILs....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to CTLA-4 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunomodulation

Share to Ipilimumab

Share to Lymphocyte Activation

Share to Lymphocytes, Tumor-Infiltrating

Share to Neoplasm Grading

Share to T-Cell Antigen Receptor Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 28423678
DOI: 10.18632/oncotarget.16003
PMCID: PMC5432318

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.PMID 28423678Read ↗

Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to IpilimumabSemantic proximity Read ↗

Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.Semantic proximity Read ↗

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.Semantic proximity Read ↗

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudySemantic proximity Read ↗

Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.Semantic proximity Read ↗

Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival.Semantic proximity Read ↗

Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.Semantic proximity Read ↗

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.Semantic proximity Read ↗

Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanomaSemantic proximity Read ↗

Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumabSemantic proximity Read ↗

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced MelanomaSemantic proximity Read ↗

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.